Use of Sponge-Foam Inserts in Compression Bandaging of Non-Healing Venous Leg Ulcers.

Venous leg ulcers (VLUs) caused by chronic venous insufficiency are difficult to treat. Outcomes after compression therapy and the current standard of care often used in conjunction with other options vary widely. We examined the effects of foam inserts on sub-bandage pressures in patients with VLUs and compared use of foam inserts in elastic and inelastic compression bandaging.

Thermal and Photochemical Control of Molecular Orientation of Azo-Functionalized Polymer Liquid Crystals and Application for Photo-Rewritable Paper.

A photo-responsive multi-bilayered film consisting of azobenzene polymer liquid crystals (PA6Az1) and poly(vinyl alcohol) (PVA) has been prepared on a glass substrate by alternate spin coating of the polymer solutions. The reflectivity of the multi-bilayered film disappears by annealing at 80 °C. The disappearance of the reflection by the annealing is related to the thermal out-of-plane molecular orientation of PA6Az1 even in the multi-bilayered film, which leads to a very small difference in refractive indices between PA6Az1 and PVA.

Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated.

Background: Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollens is a serious problem in Japan. Omalizumab, a humanized monoclonal anti-IgE antibody, improves symptoms associated with SAR, but a study comprehensively investigating the clinical efficacy, safety and pharmacological effects of omalizumab re-treatment has not yet been conducted.

Methods: The open-label, 12-week study was carried out in 34 patients who had been treated with omalizumab in the core study conducted in the previous Japanese cedar pollen season.

Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis.

Background: Seasonal allergic rhinitis (SAR) induced by Japanese cedar pollen is a substantial problem in Japan. Omalizumab, a novel humanized monoclonal anti-immunoglobulin E (IgE) antibody, has already been proven to reduce symptoms associated with SAR. We investigated the safety and efficacy of omalizumab in the treatment of patients with Japanese cedar pollen-induced SAR compared to placebo.

[Evaluation of quality of life (QOL) and efficacy of drug therapy on nasal symptoms and QOL disturbances in the patients with Japanese Cedar Pollinosis during the season of 2003 in Kyushu and Okinawa districts].

Aim: The aim of the study is to investigate nasal symptom severity (NSS) and disturbance of quality of life (QOLD) of patients with Japanese Cedar Pollinosis (JCP) during the JC season of 2003, and to evaluate the efficacy of drug treatment on the NSS/QOLD by the data based on disease specific Japan Rhino-conjunctivitis Quality of Life Questionnaire (JRQLQ).

Subjects, Methods And Results: 3173 patients with JCP from 149 clinics of 8 prefectures in Kyushu and Okinawa districts were subjected. Degree of NSS/QOLD was scored as 1 to 4 in order (1 for a little and 4 for extremely severe or bothered respectively).